Skip to main content
SpringerLink
Log in
Book cover

Cancer Prevention pp 85–105Cite as

Methods to Analyze Chemopreventive Effect of Silibinin on Prostate Cancer Biomarkers Protein Expression

  • Protocol
  • First Online:

Part of the book series: Methods in Pharmacology and Toxicology ((MIPT))

Abstract

Prostate cancer is now diagnosed mostly at an early stage, and therefore, chemopreventive strategies could be useful to prevent further progression of the disease and to reduce the morbidity and mortality due to this malignancy. Here, we have described methods (immunoblotting, immunofluorescence, and immunohistochemistry) that could be employed to screen and validate the effect of chemopreventive agents on the protein expression of various cancer-related biomarkers for proliferation, apoptosis, angiogenesis, and metastasis. As an example, we have discussed chemopreventive efficacy of silibinin against prostate cancer as well as its effect on several molecular biomarkers associated with this malignancy. Overall, the methods used to study cancer biomarker protein expression that we describe in this chapter are extremely useful in cancer chemopreventive studies.

This is a preview of subscription content, log in via an institution.

Protocol
USD   49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Springer Nature is developing a new tool to find and evaluate Protocols. Learn more

References

  1. Siegel R, Naishadham D, Jemal A (2012) Cancer statistics, 2012. Cancer J Clin 62(1):10–29. doi:10.3322/caac.20138

    Article  Google Scholar 

  2. Kingsley LA, Fournier PG, Chirgwin JM, Guise TA (2007) Molecular biology of bone metastasis. Mol Cancer Ther 6(10):2609–2617

    Article  PubMed  CAS  Google Scholar 

  3. Tantivejkul K, Kalikin LM, Pienta KJ (2004) Dynamic process of prostate cancer metastasis to bone. J Cell Biochem 91(4):706–717

    Article  PubMed  CAS  Google Scholar 

  4. Hadaschik BA, Gleave ME (2007) Therapeutic options for hormone-refractory prostate cancer in 2007. Urol Oncol 25(5):413–419

    Article  PubMed  CAS  Google Scholar 

  5. Koivisto P, Kolmer M, Visakorpi T, Kallioniemi OP (1998) Androgen receptor gene and hormonal therapy failure of prostate cancer. Am J Pathol 152(1):1–9

    PubMed  CAS  Google Scholar 

  6. Feldman BJ, Feldman D (2001) The development of androgen-independent prostate cancer. Nat Rev Cancer 1(1):34–45

    Article  PubMed  CAS  Google Scholar 

  7. Harzstark AL, Ryan CJ (2008) Novel therapeutic strategies in development for prostate cancer. Expert Opin Investig Drugs 17(1):13–22

    Article  PubMed  CAS  Google Scholar 

  8. Petrylak DP (2005) The current role of chemotherapy in metastatic hormone-refractory prostate cancer. Urology 65(Suppl 5):3–7, Discussion 7–8

    Article  PubMed  Google Scholar 

  9. Deep G, Agarwal R (2007) Chemopreventive efficacy of silymarin in skin and prostate cancer. Integr Cancer Ther 6(2):130–145. doi:10.1177/1534735407301441

    Google Scholar 

  10. Wattenberg LW (1997) An overview of chemoprevention: current status and future prospects. Proc Soc Exp Biol Med 216(2):133–141

    Article  PubMed  CAS  Google Scholar 

  11. Agarwal R (2000) Cell signaling and regulators of cell cycle as molecular targets for prostate cancer prevention by dietary agents. Biochem Pharmacol 60(8):1051–1059

    Article  PubMed  CAS  Google Scholar 

  12. Surh YJ (2003) Cancer chemoprevention with dietary phytochemicals. Nat Rev Cancer 3(10):768–780

    Article  PubMed  CAS  Google Scholar 

  13. Raina K, Rajamanickam S, Singh RP, Deep G, Chittezhath M, Agarwal R (2008) Stage-specific inhibitory effects and associated mechanisms of silibinin on tumor progression and metastasis in transgenic adenocarcinoma of the mouse prostate model. Cancer Res 68(16):6822–6830. doi:10.1158/0008-5472.CAN-08-1332

    Google Scholar 

  14. Deep G, Agarwal R (2010) Antimetastatic efficacy of silibinin: molecular mechanisms and therapeutic potential against cancer. Cancer Metastasis Rev 29(3):447–463. doi:10.1007/s10555-010-9237-0

    Article  PubMed  CAS  Google Scholar 

  15. Singh RP, Agarwal R (2006) Mechanisms of action of novel agents for prostate cancer chemoprevention. Endocr Relat Cancer 13(3):751–778

    Article  PubMed  CAS  Google Scholar 

  16. Kavitha CV, Deep G, Gangar SC, Jain AK, Agarwal C, Agarwal R (2012) Silibinin inhibits prostate cancer cells- and RANKL-induced osteoclastogenesis by targeting NFATc1, NF-kappaB, and AP-1 Activation in RAW264.7 cells. Mol Carcinog. doi:10.1002/mc.21959

  17. Agarwal R, Agarwal C, Ichikawa H, Singh RP, Aggarwal BB (2006) Anticancer potential of silymarin: from bench to bed side. Anticancer Res 26(6B):4457–4498

    PubMed  CAS  Google Scholar 

  18. Pradhan SC, Girish C (2006) Hepatoprotective herbal drug, silymarin from experimental pharmacology to clinical medicine. Indian J Med Res 124(5):491–504

    PubMed  CAS  Google Scholar 

  19. Deep G, Gangar SC, Agarwal C, Agarwal R (2011) Role of E-cadherin in antimigratory and antiinvasive efficacy of silibinin in prostate cancer cells. Cancer Prev Res (Phila) 4(8):1222–1232. doi:1940-6207.CAPR-10-0370. 10.1158/1940-6207.CAPR-10-0370

    Google Scholar 

  20. Flaig TW, Glode M, Gustafson D, van Bokhoven A, Tao Y, Wilson S, Su LJ, Li Y, Harrison G, Agarwal R, Crawford ED, Lucia MS, Pollak M (2010) A study of high-dose oral silybin-phytosome followed by prostatectomy in patients with localized prostate cancer. J Prostate 70(8):848–855. doi:10.1002/pros.21118

    CAS  Google Scholar 

  21. Flaig TW, Gustafson DL, Su LJ, Zirrolli JA, Crighton F, Harrison GS, Pierson AS, Agarwal R, Glode LM (2007) A phase I and pharmacokinetic study of silybin-phytosome in prostate cancer patients. Investig New Drugs 25(2):139–146

    Article  CAS  Google Scholar 

  22. Hoh C, Boocock D, Marczylo T, Singh R, Berry DP, Dennison AR, Hemingway D, Miller A, West K, Euden S, Garcea G, Farmer PB, Steward WP, Gescher AJ (2006) Pilot study of oral silibinin, a putative chemopreventive agent, in colorectal cancer patients: silibinin levels in plasma, colorectum, and liver and their pharmacodynamic consequences. Clin Cancer Res 12(9):2944–2950

    Article  PubMed  CAS  Google Scholar 

  23. Singh RP, Deep G, Chittezhath M, Kaur M, Dwyer-Nield LD, Malkinson AM, Agarwal R (2006) Effect of silibinin on the growth and progression of primary lung tumors in mice. J Natl Canc Inst 98(12):846–855

    Article  CAS  Google Scholar 

  24. Roy S, Gu M, Ramasamy K, Singh RP, Agarwal C, Siriwardana S, Sclafani RA, Agarwal R (2009) p21/Cip1 and p27/Kip1 are essential molecular targets of inositol hexaphosphate for its antitumor efficacy against prostate cancer. Cancer Res 69(3):1166–1173. doi:10.1158/0008-5472.CAN-08-3115

    Google Scholar 

  25. Tyagi A, Sharma Y, Agarwal C, Agarwal R (2008) Silibinin impairs constitutively active TGFalpha-EGFR autocrine loop in advanced human prostate carcinoma cells. Pharm Res, 25:2143–2150

    Google Scholar 

  26. Zi X, Grasso AW, Kung HJ, Agarwal R (1998) A flavonoid antioxidant, silymarin, inhibits activation of erbB1 signaling and induces cyclin-dependent kinase inhibitors, G1 arrest, and anticarcinogenic effects in human prostate carcinoma DU145 cells. Cancer Res 58(9):1920–1929

    PubMed  CAS  Google Scholar 

  27. Singh RP, Agarwal R (2006) Prostate cancer chemoprevention by silibinin: bench to bedside. Mol Carcinog 45(6):436–442

    Article  PubMed  CAS  Google Scholar 

  28. Deep G, Gangar SC, Rajamanickam S, Raina K, Gu M, Agarwal C, Oberlies NH, Agarwal R (2012) Angiopreventive efficacy of pure flavonolignans from milk thistle extract against prostate cancer: targeting VEGF-VEGFR signaling. PloS One 7(4):e34630. doi:10.1371/journal.pone.0034630

    Article  PubMed  CAS  Google Scholar 

  29. Singh RP, Dhanalakshmi S, Agarwal C, Agarwal R (2005) Silibinin strongly inhibits growth and survival of human endothelial cells via cell cycle arrest and downregulation of survivin, Akt and NF-kappaB: implications for angioprevention and antiangiogenic therapy. Oncogene 24(7):1188–1202

    Article  PubMed  CAS  Google Scholar 

  30. Deep G, Agarwal R (2013) Targeting tumor microenvironment with silibinin: promise and potential for a translational cancer chemopreventive strategy. Curr Cancer Drug Target 13:486–499

    Google Scholar 

  31. Singh RP, Raina K, Sharma G, Agarwal R (2008) Silibinin inhibits established prostate tumor growth, progression, invasion, and metastasis and suppresses tumor angiogenesis and epithelial-mesenchymal transition in transgenic adenocarcinoma of the mouse prostate model mice. Clin Cancer Res 14(23):7773–7780. doi:10.1158/1078-0432.CCR-08-1309

  32. Deep G, Singh RP, Agarwal C, Kroll DJ, Agarwal R (2006) Silymarin and silibinin cause G1 and G2-M cell cycle arrest via distinct circuitries in human prostate cancer PC3 cells: a comparison of flavanone silibinin with flavanolignan mixture silymarin. Oncogene 25(7):1053–1069

    Article  PubMed  CAS  Google Scholar 

  33. Zi X, Agarwal R (1999) Silibinin decreases prostate-specific antigen with cell growth inhibition via G1 arrest, leading to differentiation of prostate carcinoma cells: implications for prostate cancer intervention. Proc Natl Acad Sci U S A 96(13):7490–7495

    Article  PubMed  CAS  Google Scholar 

  34. Singh RP, Raina K, Deep G, Chan D, Agarwal R (2009) Silibinin suppresses growth of human prostate carcinoma PC-3 orthotopic xenograft via activation of extracellular signal-regulated kinase 1/2 and inhibition of signal transducers and activators of transcription signaling. Clin Cancer Res 15(2):613–621. doi:10.1158/1078-0432.CCR-08-1846

  35. Singh RP, Deep G, Blouin MJ, Pollak MN, Agarwal R (2007) Silibinin suppresses in vivo growth of human prostate carcinoma PC-3 tumor xenograft. Carcinogenesis 28(12):2567–2574. doi:10.1093/carcin/bgm218

    Google Scholar 

  36. Singh RP, Dhanalakshmi S, Tyagi AK, Chan DC, Agarwal C, Agarwal R (2002) Dietary feeding of silibinin inhibits advance human prostate carcinoma growth in athymic nude mice and increases plasma insulin-like growth factor-binding protein-3 levels. Cancer Res 62(11):3063–3069

    PubMed  CAS  Google Scholar 

  37. Raina K, Blouin MJ, Singh RP, Majeed N, Deep G, Varghese L, Glode LM, Greenberg NM, Hwang D, Cohen P, Pollak MN, Agarwal R (2007) Dietary feeding of silibinin inhibits prostate tumor growth and progression in transgenic adenocarcinoma of the mouse prostate model. Cancer Res 67(22):11083–11091

    Article  PubMed  CAS  Google Scholar 

  38. Zhu W, Zhang JS, Young CY (2001) Silymarin inhibits function of the androgen receptor by reducing nuclear localization of the receptor in the human prostate cancer cell line LNCaP. Carcinogenesis 22(9):1399–1403

    Article  PubMed  CAS  Google Scholar 

  39. Thelen P, Wuttke W, Jarry H, Grzmil M, Ringert RH (2004) Inhibition of telomerase activity and secretion of prostate specific antigen by silibinin in prostate cancer cells. J Urol 171(5):1934–1938

    Article  PubMed  CAS  Google Scholar 

  40. Hansen J, Rink M, Graefen M, Shariat S, Chun FK (2013) Assays for prostate cancer : changing the screening paradigm? Mol Diagn Ther 17(1):1–8. doi:10.1007/s40291-013-0014-y

    Article  PubMed  Google Scholar 

  41. Singh RP, Sharma G, Dhanalakshmi S, Agarwal C, Agarwal R (2003) Suppression of advanced human prostate tumor growth in athymic mice by silibinin feeding is associated with reduced cell proliferation, increased apoptosis, and inhibition of angiogenesis. Cancer Epidemiol Biomarkers Prev 12(9):933–939

    PubMed  CAS  Google Scholar 

  42. Deep G, Raina K, Singh RP, Oberlies NH, Kroll DJ, Agarwal R (2008) Isosilibinin inhibits advanced human prostate cancer growth in athymic nude mice: comparison with silymarin and silibinin. Int J Cancer 123(12):2750–2758. doi:10.1002/ijc.23879

    Article  PubMed  CAS  Google Scholar 

  43. Zi X, Zhang J, Agarwal R, Pollak M (2000) Silibinin up-regulates insulin-like growth factor-binding protein 3 expression and inhibits proliferation of androgen-independent prostate cancer cells. Cancer Res 60(20):5617–5620

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, Aurora, CO, USA

    Gagan Deep, Swetha Inturi & Rajesh Agarwal

  2. University of Colorado Cancer Center, University of Colorado, Aurora, CO, USA

    Gagan Deep, Swetha Inturi & Rajesh Agarwal

Authors
  1. Gagan Deep
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Swetha Inturi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Rajesh Agarwal
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. The Hormel Institute, Austin, Minnesota, USA

    Ann M. Bode

  2. The Hormel Institute, Austin, Minnesota, USA

    Zigang Dong

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer Science+Business Media New York

About this protocol

Cite this protocol

Deep, G., Inturi, S., Agarwal, R. (2014). Methods to Analyze Chemopreventive Effect of Silibinin on Prostate Cancer Biomarkers Protein Expression. In: Bode, A., Dong, Z. (eds) Cancer Prevention. Methods in Pharmacology and Toxicology. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4614-9227-6_4

Download citation

  • DOI: https://doi.org/10.1007/978-1-4614-9227-6_4

  • Published:

  • Publisher Name: Humana Press, New York, NY

  • Print ISBN: 978-1-4614-9226-9

  • Online ISBN: 978-1-4614-9227-6

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics

Search

Navigation